Downregulation of MiR-30a is Associated with Poor Prognosis in Lung Cancer

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2015 Aug 26

PMID 26305739

Citations 28

Authors

Ruixue Tang

Lu Liang

Dianzhong Luo

Zhenbo Feng

Qiuxia Huang

Rongquan He

Tingqing Gan

Lihua Yang

Gang Chen

Affiliations

Soon will be listed here.

Abstract

Background: Recent reports have suggested that miR-30a plays a tumor-suppressive role in various cancers. However, miR-30a has not been completely studied in non-small lung cancer (NSCLC). Thus, the aim of the present study was to clarify the association between the expression of miR-30a and the clinicopathological features in NSCLC patients.

Material And Methods: Total RNA of miR-30a was extracted from 125 pairs of NSCLC patients (male 75, female 50) and their matching normal tissues. The miR-30a level was detected by using quantitative real-time polymerase chain reaction (qRT-PCR). Simultaneously, the 2-ΔCq method was used to calculate the correlation between miR-30a expression and the clinicopathological parameters and prognosis of NSCLC patients.

Results: MiR-30a expression was significantly down-regulated in NSCLC tissues (4.0696±2.4178) compared to their non-tumor lung tissues (7.4530±3.0561, P<0.001). Level of miR-30a was negatively correlated to tumor size (r=-0.197, P=0.028), lymphatic metastasis (r=-0.312, P<0.001), clinical TNM stage (r=-0.299, P=0.001), pathological grading (I/II vs. III, r=-0.224, P=0.001), and histological classification (r=-0.299, P=0.001). Survival time was 3.23±2.18 months in the low miR-30a expression group, remarkably shorter than that of the high expression group (20.72±11.63 months, P<0.001).

Conclusions: MiR-30a may be regarded as a tumor suppressor in NSCLC, and it could become a prognostic marker and potential therapeutic target for NSCLC.

Citing Articles

Phosphorylated nuclear DICER1 promotes open chromatin state and lineage plasticity of AT2 tumor cells in lung adenocarcinomas.

Reyes-Castro R, Chen S, Seemann J, Kundu S, Gibbons D, Arur S Sci Adv. 2023; 9(30):eadf6210.

PMID: 37494452 PMC: 10371025. DOI: 10.1126/sciadv.adf6210.

EpiMix: an integrative tool for epigenomic subtyping using DNA methylation.

Zheng Y, Jun J, Brennan K, Gevaert O bioRxiv. 2023; .

PMID: 36711917 PMC: 9881910. DOI: 10.1101/2023.01.03.522660.

Molecular Characterization of the Response to Conventional Chemotherapeutics in Pro-B-ALL Cell Lines in Terms of Tumor Relapse.

Gladbach Y, Sklarz L, Roolf C, Beck J, Schutz E, Fuellen G Genes (Basel). 2022; 13(7).

PMID: 35886023 PMC: 9316692. DOI: 10.3390/genes13071240.

Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis.

MotieGhader H, Safavi E, Rezapour A, Amoodizaj F, Asl Iranifam R Sci Rep. 2021; 11(1):21872.

PMID: 34750486 PMC: 8576023. DOI: 10.1038/s41598-021-01410-3.

Increased microRNA-30a levels in bronchoalveolar lavage fluid as a diagnostic biomarker for lung cancer.

Zhu W, Chen B, Zhu Y, Sun L, Zhang Y, Liu H PeerJ. 2021; 9:e11528.

PMID: 34178448 PMC: 8197034. DOI: 10.7717/peerj.11528.

References

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

Rong M, He R, Dang Y, Chen G . Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Ups J Med Sci. 2013; 119(1):19-24. PMC: 3916713. DOI: 10.3109/03009734.2013.856970. View

Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J . MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer. 2011; 130(9):2044-53. DOI: 10.1002/ijc.26218. View

Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y . Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010; 28(10):1721-6. DOI: 10.1200/JCO.2009.24.9342. View

Chen G, Kronenberger P, Umelo I, Teugels E, De Greve J . Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Anal Biochem. 2009; 398(2):266-8. DOI: 10.1016/j.ab.2009.11.034. View

Erkan M, Weis N, Pan Z, Schwager C, Samkharadze T, Jiang X . Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Mol Cancer. 2010; 9:88. PMC: 2876060. DOI: 10.1186/1476-4598-9-88. View

Qian B, Nag S, Su Y, Voruganti S, Qin J, Zhang R . miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents. Curr Cancer Drug Targets. 2013; 13(5):519-41. DOI: 10.2174/15680096113139990031. View

Jiang B, Zhang X, Su J, Meng W, Yang X, Yang J . BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification. Mol Cancer. 2013; 12:61. PMC: 3695801. DOI: 10.1186/1476-4598-12-61. View

Chen G, Kronenberger P, Teugels E, Umelo I, De Greve J . Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012; 10:28. PMC: 3334713. DOI: 10.1186/1741-7015-10-28. View

10.

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

11.

Chen G, Noor A, Kronenberger P, Teugels E, Umelo I, De Greve J . Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One. 2013; 8(3):e59708. PMC: 3601073. DOI: 10.1371/journal.pone.0059708. View

12.

Zhang Q, Tang Q, Qin D, Yu L, Huang R, Lv G . Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis. Mol Cell Biol. 2015; 35(6):988-1000. PMC: 4333091. DOI: 10.1128/MCB.01242-14. View

13.

Di Leva G, Briskin D, Croce C . MicroRNA in cancer: new hopes for antineoplastic chemotherapy. Ups J Med Sci. 2012; 117(2):202-16. PMC: 3339552. DOI: 10.3109/03009734.2012.660551. View

14.

Liu K, Guo L, Guo Y, Zhou B, Li T, Yang H . AEG-1 3'-untranslated region functions as a ceRNA in inducing epithelial-mesenchymal transition of human non-small cell lung cancer by regulating miR-30a activity. Eur J Cell Biol. 2014; 94(1):22-31. DOI: 10.1016/j.ejcb.2014.10.006. View

15.

Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J . miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2. Biochem Biophys Res Commun. 2014; 445(2):314-9. DOI: 10.1016/j.bbrc.2014.01.174. View

16.

Chen G, Umelo I, Lv S, Teugels E, Fostier K, Kronenberger P . miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One. 2013; 8(3):e60317. PMC: 3608584. DOI: 10.1371/journal.pone.0060317. View

17.

Dai H, Kang B, Zuo D, Zuo G . [Effect of miR-30a-5p on the proliferation, apoptosis, invasion and migration of SMCC-7721 human hepatocellular carcinoma cells]. Zhonghua Gan Zang Bing Za Zhi. 2015; 22(12):915-20. DOI: 10.3760/cma.j.issn.1007-3418.2014.12.008. View

18.

Wang H, Li Y, Fu S, Wang X, Huang M, Zhang X . MicroRNA-30a promotes invasiveness and metastasis in vitro and in vivo through epithelial-mesenchymal transition and results in poor survival of nasopharyngeal carcinoma patients. Exp Biol Med (Maywood). 2014; 239(7):891-898. DOI: 10.1177/1535370214532758. View

19.

Voortman J, Goto A, Mendiboure J, Sohn J, Schetter A, Saito M . MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res. 2010; 70(21):8288-98. PMC: 2970724. DOI: 10.1158/0008-5472.CAN-10-1348. View

20.

Patnaik S, Kannisto E, Knudsen S, Yendamuri S . Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 2009; 70(1):36-45. DOI: 10.1158/0008-5472.CAN-09-3153. View